<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738267</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01220-55</org_study_id>
    <nct_id>NCT03738267</nct_id>
  </id_info>
  <brief_title>Study on the Occurrence of Head and Neck Cancers During Pregnancy</brief_title>
  <acronym>REFCORbirth</acronym>
  <official_title>Study on the Occurrence of Head and Neck Cancers During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French scientific group REFCOR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Head and neck cancers that occurred during pregnancy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serological status of patients</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Number of patients with positive or negative serological status for PVH (Papilloma Virus Humain) and EBV (Epstein-Barr Virus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics pregnancy of patients</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Presence or absence of maternal-fetal diseases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor characteristics of patients</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Histological type of cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor characteristics of patients</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Localization of cancer</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Pregnancy Related</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancers of Head and Neck that occurred during pregnancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 year old woman or over at the time of participation

          -  PS 0 -2

          -  Cancer diagnosed (biopsy date) from 01/01/2010 between the second week of pregnancy
             and the 12 months postpartum.

          -  Primitive may concern the following sites:

        oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, prevalent lymphadenopathy, nasal
        cavity, salivary glands, dental tumors, ear tumors, paragangliomas optic pathways, facial
        sinus / facial mass, nose, ear and other head and neck

          -  All histologies (epithelial tumors, sarcomas, mucosal melanomas, embryonic tumors,
             undifferentiated tumors)

          -  Patient receiving or having received a specific oncological treatment among surgery,
             radiotherapy, chemotherapy, hormone therapy.

          -  All stages allowed: localized stages and metastatic stages immediately.

          -  No opposition of the patient to participate in this study

        Exclusion Criteria:

          -  Any other neoplastic antecedent

          -  Exclusion of metastases at the level of the VADS of another primitive than a cancer of
             the VADS

          -  Exclusion of hematological tumors (lymphoma) and glial tumors

          -  Person subject to a legal protection measure or unable to express their consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MAUVAIS, MD</last_name>
      <email>omauvais@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic Le Taillandier DE gabory, Prof</last_name>
      <email>ludovic.de-gabory@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliette THARIAT, Prof</last_name>
      <phone>0231455020</phone>
      <email>j.thariat@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Righini, MD</last_name>
      <email>crighini@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ap-Hp Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand BAUJAT, MD</last_name>
      <email>bertrand.baujat@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Dufour, MD</last_name>
      <email>xavier.dufour@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien VERGEZ, MD</last_name>
      <email>vergez.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy IGR</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid BREUSKIN, MD</last_name>
      <email>Ingrid.BREUSKIN@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Ingrid BREUSKIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

